share_log

盟科药业(688373.SH):MRX-5临床试验申请获批准

Mengke Pharmaceutical (688373.SH): The clinical trial application for MRX-5 has been approved.

Zhitong Finance ·  Jan 3 15:34

Mengke Pharmaceutical (688373.SH) announced that the company recently received a notice from the National Medical Products Administration regarding MRX...

According to the Zhitong Caijing APP, Mengke Pharmaceuticals (688373.SH) announced that the company recently received a "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for MRX-5 tablets used in the treatment of infections caused by non-tuberculous mycobacteria sensitive to this product. The announcement shows that MRX-5 is a new type of benzo-borazole class antibiotic intended for the treatment of mycobacterial infections, particularly those caused by NTM.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment